- The disease
- Non-segmental vitiligo is a chronic skin condition in which the immune system destroys melanocytes, the cells responsible for producing pigment, leading to irregular white patches across the body. It is the most common form of vitiligo and can affect any skin area, including the face and hands. The condition is not life-threatening but carries a recognised psychological and quality-of-life burden. It disproportionately affects people with darker skin tones, the population targeted in this trial (Fitzpatrick skin types III through VI).
- What the asset is trying to do
- SCENESSE (afamelanotide) is a synthetic peptide that acts as an agonist at the melanocortin-1 receptor (MC1R), a receptor found on melanocytes that, when activated, stimulates melanin (pigment) production. In this trial, afamelanotide is combined with narrowband ultraviolet-B (NB-UVB) phototherapy, a standard light-based treatment for vitiligo, with the rationale that priming melanocytes with the peptide may enhance the skin's response to light therapy. This combination approach differs from stand-alone NB-UVB by adding a pharmacological stimulus to melanocyte activity prior to light exposure.
- What the trial is measuring, and why it matters
- The lead trial (NCT06109649) compares afamelanotide plus NB-UVB against NB-UVB alone in patients with non-segmental vitiligo (per ClinicalTrials.gov NCT06109649). The primary completion date listed on the registry is 2025-12-01, with the company noting topline results are expected in the second half of 2026. Efficacy and safety are the stated study objectives; specific endpoint definitions (such as the validated Vitiligo Area Scoring Index or similar repigmentation measures) are not detailed in the available input data and should be confirmed from the full protocol.
- Efficacy benchmarks in this setting
- In non-segmental vitiligo, approved therapies include ruxolitinib cream (a JAK inhibitor approved by the FDA in 2022 under the brand name Opzelura), which in the Phase 3 TRuE-V trials achieved a F-VASI75 response (at least 75% improvement in facial Vitiligo Area Scoring Index) in approximately 30% of patients at 24 weeks versus approximately 8% for vehicle (per Rosmarin et al, New England Journal of Medicine, 2022). NB-UVB phototherapy is used as a standard of care but repigmentation outcomes vary widely across studies and patient populations. Any early-stage or interim figures from this afamelanotide trial are not statistically comparable to these established benchmarks given differences in study design, endpoints, and patient populations.